Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (328)	9/17/2008 2:42:49 PM
From: tuck	Read Replies (1) \| Respond to of 684

NOVC is reverse merging into something else, and AGIX is going into BK. One, of course must think about converts and debt as well as burn. I like Nektar best on this list in terms of being able to survive and maybe bring something new to market. FWIW. Cheers, Tuck

To: rkrw who wrote (328)	9/17/2008 10:43:28 PM
From: ghmm	Read Replies (1) \| Respond to of 684

The 130 number seemed high to me too but the way things have been going I wouldn't be shocked. I have followed NTII for a while I thought Viprinex too speculative and with losing the Memantine royalty and pain indication potential along with selling XERECEPT my interest really dwindled. The last financing (recapitalization) really left me with a soar taste (I had thought Freiman was a shareholder friendly CEO till then) and I lost all interest but still curious about what will happen with Viprinex. Thanks for the list I'll have to look through some that I am not too familiar with. Unfortunately the ones I am familiar with a burn cash much faster then creating value. Not too many TKT's around these days :).